RGNX
REGENXBIOANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
RGX-202 has reported positive pivotal data, while the AbbVie-linked retinal program adds multiple late-stage opportunities and near-term milestone cash. The upside case depends on regulatory progress, durable functional benefit, and successful retinal readouts.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -0.3.
What can break
Cash burn, manufacturing scale-up, partnership economics, and future financing could pressure runway.
Momentum
99
Value
41
Sentiment
62
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $10.50 · Bull $18.50 · Bear $6.50
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $26.08
Why
Momentum99 · Δ7d -0.3
Value41 · Δ7d -0.1
Sentiment62 · Δ7d +16.2
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
99
26% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
+29.2
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
62
34% active weight
Current posture
7d trendImproving
Δ7d
+16.2
Δ21d
-
Why this grade
Composite grade A. Momentum 98.6 / Value 41.1 / Sentiment 61.9
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$511.29M
Beta
1.06
Shares Out
51.7M
P/E (TTM) · Derived
-2.6
P/S (TTM)
4.21
P/FCF (TTM) · Derived
-2.17
Rev YoY
-92.8%
EPS YoY
-1551.9%
Gross Margin
+50.5%
Op Margin
-96.0%
Net Debt
$30.45M
Current Ratio
2.62
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology